North Staffordshire Clinical Commissioning Group
Stoke-on-Trent Clinical Commissioning Group
| Citalopram |
|
Formulary
|
Citalopram Hydrobromide Tablet 10mg Cost effective choice in patients where QT interval prolongation is not an issue (see MHRA advice below for detail) Maximum daily dose 40 mg for adults; 20 mg for patients older than 65 years; and 20 mg for those with hepatic impairment. |
 MHRA Guidance on Citalopram and Escitalopram: QT Interval prolongation |
|
| Sertraline |
|
Formulary
|
Sertraline (as Sertraline hydrochloride) Tablet 50mg |
|
|
| Vortioxetine |
|
Formulary
|
Vortioxetine 5mg Tablets Restriction: In line with NICE Guidance Vortioxetine is recommended as an option for treating major depressive episodes in adults whose condition has responded inadequately to 2 antidepressants within the current episode. |
|
NICE TA367 - Vortioxetine for treating major depressive episodes |
|
Links
- MHRA Guidance on Citalopram and Escitalopram: QT Interval prolongation
- NICE CG192: Antenatal and postnatal mental health: clinical management and service guidance
- NICE CG28: Depression in children and young people: identification and management
- NICE CG31: Obsessive-compulsive disorder and body dysmorphic disorder: treatment
- NICE CG53: Chronic fatigue syndrome/myalgic encephalomyelitis or encephalopathy): diagnosis and management
- NICE CG90: Depression in adults: recognition and management
- NICE CG91: Depression in adults with a chronic physical health problem: recognition and management
- NICE NG116: Post-traumatic stress disorder
- NICE TA367 - Vortioxetine for treating major depressive episodes